Abstract
Background Seasonal malaria chemoprevention (SMC) has been implemented yearly in northern Benin since 2019 to reduce the malaria burden in children under 5 years of age. Its geographic scope was progressively extended until in 2022 two different extensions of SMC were considered: either demographic - children aged 5 to 10 in the currently targeted departments would also receive SMC, or geographic to children under 5 in new eligible departments to the south. As SMC had neither been implemented in the areas nor age groups suggested for expansion, modelling was used to compare the likely impact of both extensions.
Methods The model OpenMalaria was calibrated to represent the history of malaria interventions and transmission risk in Benin. Currently planned future interventions and two scenarios for SMC extensions were simulated to inform where impact would be the highest.
Results The model predicted that between 2024 and 2026 the geographic extension of SMC would avert at least four times more severe malaria cases and five times more direct malaria deaths per targeted child than the demographic extension. However, numbers of severe cases averted per targeted child were similar between health zones eligible for geographic extension.
Conclusions The geographic extension is more impactful and likely more cost-effective than the demographic extension, and will be implemented from 2024. Health zones were prioritised by availability of community health workers to deliver SMC. Mathematical modelling was a supportive tool to understand the relative impact of the different proposed SMC extensions and contributed to the decision-making process. Its integration significantly enhanced the utilisation of data for decision-making purposes. Rather than being used for forecasting, the model provided qualitative guidance that complemented other types of evidence.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation [INV-030449].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Input data for simulations, simulation datasets and additional data necessary for analysis such as population are available upon reasonable request to the authors.
